Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-2025-04-21

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Menu

    Blarcamesine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Anavex Life Sciences Reports Positive 4-Year Blarcamesine Results
    Anavex Life Sciences Reports Positive 4-Year Blarcamesine Results

    05 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/05/3056284/29248/en/Anavex-Life-Sciences-Announces-Positive-up-to-4-Years-Oral-Blarcamesine-Results-from-Phase-IIb-III-Open-Label-Extension-Trial-in-Early-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    05 Apr 2025
    Share Share
    Anavex Expands IP With Blarcamesin U.S. Patent Issuance
    Anavex Expands IP With Blarcamesin U.S. Patent Issuance

    27 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/27/3015498/29248/en/Anavex-Life-Sciences-Announces-Issuance-of-Blarcamesine-ANAVEX-2-73-Composition-of-Matter-U-S-Patent-Expanding-its-Intellectual-Property-Portfolio.html

    GLOBENEWSWIRE
    27 Jan 2025
    Share Share
    Anavex's Alzheimer Treatment Result Published In Journal
    Anavex's Alzheimer Treatment Result Published In Journal

    15 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/15/3009934/29248/en/Anavex-Life-Sciences-Announces-Peer-Reviewed-Publication-of-Oral-Blarcamesine-Phase-IIb-III-Data-in-The-Journal-of-Prevention-of-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    15 Jan 2025
    Share Share
    Blarcamesine Receives EMA Filing Acceptance for Alzheimer’s Disease
    Blarcamesine Receives EMA Filing Acceptance for Alzheimer’s Disease

    23 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/23/3001118/29248/en/Blarcamesine-Receives-EMA-Filing-Acceptance-for-Treatment-of-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    23 Dec 2024
    Share Share
    Anavex to Report Blarcamesine Phase IIb/III Alzheimer’s Data
    Anavex to Report Blarcamesine Phase IIb/III Alzheimer’s Data

    09 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/09/2993663/29248/en/Anavex-Life-Sciences-to-Report-New-Long-Term-Oral-Blarcamesine-Phase-IIb-III-Alzheimer-s-Disease-Data-at-J-P-Morgan-2025-Healthcare-Conference.html

    GLOBENEWSWIRE
    09 Dec 2024
    Share Share
    Anavex Life's Acceptance of Blarcamesine Phase IIb/III Data Manuscript
    Anavex Life's Acceptance of Blarcamesine Phase IIb/III Data Manuscript

    25 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/25/2986572/29248/en/Anavex-Life-Sciences-Announces-Acceptance-of-Peer-Reviewed-Manuscript-of-Oral-Blarcamesine-Phase-IIb-III-Data-in-a-Reference-Alzheimer-s-Disease-Journal.html

    GLOBENEWSWIRE
    25 Nov 2024
    Share Share